mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways

Majumder, Pradip K, Febbo, Phillip G, Bikoff, Rachel, Berger, Raanan, Xue, Qi, McMahon, Louis M, Manola, Judith, Brugarolas, James +5 more·2004·Nature Medicine

Cited by (962)

Items 701–800 of 962

  1. Building on a foundation of VEGF and mTOR targeted agents in renal cell carcinoma
    Keith T. Flaherty, Igor J. Puzanov · 2010 · Biochemical Pharmacology
  2. Inhibition of mTOR signaling by rapamycin protects photoreceptors from degeneration in rd1 mice
    Jialiang Yang, 电子科技大学附属四川省人民医院人类疾病基因四川省重点实验室,四川 成都 610072,中国, Tongdan Zou, Fang Yang, Zhenglin Yang, Houbin Zhang, 中国科学院四川省转化医学医院,成都生物研究所,四川 成都 610072,中国, 中国医学科学院防盲研究中心,四川省医学科学院四川省人民医院,四川 成都 610072,中国 · 2021 · 动物学研究
  3. A gene transcription signature associated with hormone independence in a subset of both breast and prostate cancers
    Chad J. Creighton · 2007 · BMC Genomics
  4. Investigating mammalian target of rapamycin inhibitors for their anticancer properties
    Piotr Smolewski · 2006 · Expert Opinion on Investigational Drugs
  5. Tumour suppressors in liver carcinogenesis
    Jean‐François Dufour, Otmar Huber, Sara C. Kozma, Xin Lü, Rune Toftgård · 2007 · Journal of Hepatology
  6. Understanding the relationship between cancer associated cachexia and hypoxia-inducible factor-1
    Subramanian Muthamil, Hyun Yong Kim, Hyun‐Jun Jang, Ji‐Hyo Lyu, Ung Cheol Shin, Younghoon Go, Seong‐Hoon Park, Hee Gu Lee, Jun Hong Park · 2023 · Biomedicine & Pharmacotherapy
  7. Phase 1b study of the mammalian target of rapamycin inhibitor sirolimus in combination with nanoparticle albumin–bound paclitaxel in patients with advanced solid tumors
    Maysa M Abu-Khalaf, Megan Ann Baumgart, Scott N. Gettinger, Indukala Doddamane, David P. Tuck, Shihe Hou, Nianhang Chen, Catherine A.W. Sullivan, Kimberly Lezon-Geyda, Daniel A. Zelterman et al. · 2015 · Cancer
  8. Castration-resistant prostate cancer: potential targets and therapies
    Mohammad Saleem, Hifzur Rahman Siddique, Badrinath R. Konety, Sanjeev Nanda, Parray · 2012 · Biologics
  9. Unique roles of estrogen-dependent Pten control in epithelial cell homeostasis of mouse vagina
    Shinichi Miyagawa, Masaru Satô, Tamotsu Sudo, Gen Yamada, Taisen Iguchi · 2014 · Oncogene
  10. Trimming of mammalian transcriptional networks using network component analysis
    Linh My Tran, Daniel R. Hyduke, James C. Liao · 2010 · BMC Bioinformatics
  11. Targeting the mTOR Pathway in Tumor Malignancy
    Hengmiao Cheng, Marlena Walls, Sangita M. Baxi, Min-Jean Yin · 2013 · Current Cancer Drug Targets
  12. From man to mouse and back again: advances in defining tumor AKTivities in vivo
    David F. Restuccia, Brian A. Hemmings · 2010 · Disease Models & Mechanisms
  13. Akt, hexokinase, mTOR: Targeting cellular energy metabolism for cancer therapy
    R. Brooks Robey, Nissim Hay · 2005 · Drug Discovery Today Disease Mechanisms
  14. α-Enolase Lies Downstream of mTOR/HIF1α and Promotes Thyroid Carcinoma Progression by Regulating CST1
    Yang Liu, Lida Liao, Changming An, Xiaolei Wang, Zhengjiang Li, Zhen-gang Xu, Jie Liu, Shaoyan Liu · 2021 · Frontiers in Cell and Developmental Biology
  15. mTOR Signaling: Roles in Hepatitis B Virus Infection and Hepatocellular Carcinoma
    Ling Mei, Huizhen Sun, Ying Yan, Huimin Ji, Qian Su, Le Chang, Lunan Wang · 2024 · International Journal of Biological Sciences
  16. Clinical development of kinase inhibitors for the treatment of differentiated thyroid cancer.
    Alan Loh Ho, Eric Jeffrey Sherman · 2011 · PubMed
  17. Extracellular Vesicles Induce an Aggressive Phenotype in Luminal Breast Cancer Cells Via PKM2 Phosphorylation
    Seo Young Kang, Eun Ji Lee, Jung Woo Byun, Dohyun Han, Yoori Choi, Do Won Hwang, Dong Soo Lee · 2021 · Frontiers in Oncology
  18. AQP9 suppresses hepatocellular carcinoma cell invasion through inhibition of hypoxia‐inducible factor 1α expression under hypoxia
    Yanzhi Qian, Fengchao Liu, Wenguang Zhang, Xi Emily Zheng, Shengtao Liao, Lin Lv, Zhechuan Mei · 2020 · Journal of Gastroenterology and Hepatology
  19. TORward AKTually useful mouse models
    Ingo K. Mellinghoff, Charles L. Sawyers · 2004 · Nature Medicine
  20. From Vessels to Neurons—The Role of Hypoxia Pathway Proteins in Embryonic Neurogenesis
    Barbara Krystyna Stepien, Ben Wielockx · 2024 · Cells
  21. High EIF4EBP1 expression reflects mTOR pathway activity and cancer cell proliferation and is a biomarker for poor breast cancer prognosis
    Erek Nelson · 2024 · American Journal of Cancer Research
  22. Extracellular Signal-Regulated Kinase 5 and Cyclic AMP Response Element Binding Protein Are Novel Pathways Inhibited by Vandetanib (ZD6474) and Doxorubicin in Mesotheliomas
    Mutlay Sayan, Arti Shukla, Maximilian B. MacPherson, Sherrill L. Macura, Jedd Hillegass, Timothy N. Perkins, Joyce K. Thompson, Stacie L. Beuschel, Jill M. Miller, Brooke Taylor Mossman · 2014 · American Journal of Respiratory Cell and Molecular Biology
  23. Weighted gene coexpression network analysis identifies hub genes related to KRAS mutant lung adenocarcinoma
    Dongjun Dai, Rongkai Shi, Shuting Han, Hongchuan Jin, Xian Wang · 2020 · Medicine
  24. MEN1 silencing aggravates tumorigenic potential of AR-independent prostate cancer cells through nuclear translocation and activation of JunD and β-catenin
    Yakun Luo, Virginie Vlaeminck‐Guillem, Silvère Baron, Sarah Dallel, Chang Xian Zhang, Muriel Le Romancer · 2021 · Journal of Experimental & Clinical Cancer Research
  25. Everolimus and Its Role in Hormone-Resistant and Trastuzumab-Resistant Metastatic Breast Cancer
    Sara Keck, Alexa Glencer, Hope S. Rugo · 2012 · Future Oncology
  26. Circular RNAs Regulate Glucose Metabolism in Cancer Cells
    Xiaoyu Ji, Wei Sun, Chengzhou Lv, Jiapeng Huang, Hao Zhang · 2021 · OncoTargets and Therapy
  27. Impact of Prostate Inflammation on Lesion Development in the POET3+ Pten Mouse Model of Prostate Carcinogenesis
    Grant N. Burcham, Gregory M. Cresswell, Paul W. Snyder, Long Chen, Xiaoqi Liu, Scott A. Crist, Michael D. Henry, Timothy L. Ratliff · 2014 · American Journal Of Pathology
  28. Sprouty2 Protein Regulates Hypoxia-inducible Factor-α (HIFα) Protein Levels and Transcription of HIFα-responsive Genes
    Kristin C. Hicks, Tarun B. Patel · 2016 · Journal of Biological Chemistry
  29. mTOR Signaling in Glioblastoma: Lessons Learned from Bench to Bedside
    David Akhavan, Paul S. Mischel · 2009 · Humana Press eBooks
  30. Monitoring Targeted Therapy: Is Fluorodeoxylucose Uptake a Marker of Early Response?
    Hannah M. Linden, Kenneth A. Krohn, Robert B. Livingston, David A. Mankoff · 2006 · Clinical Cancer Research
  31. Models of prostate cancer
    Chris Albanese, Olga Catalina Rodriguez, Michael D. Johnson, Stanley Thomas Fricke · 2005 · Drug Discovery Today Disease Models
  32. Bevacizumab plus 5-fluorouracil induce growth suppression in the CWR-22 and CWR-22R prostate cancer xenografts
    Huynh Hung · 2007 · Molecular Cancer Therapeutics
  33. Hypoxia in prostate cancer: observation to intervention
    Yaacov Richard Lawrence, Adam Paul Dicker · 2008 · The Lancet Oncology
  34. Functional imaging in predicting response to antineoplastic agents and molecular targeted therapies in lung cancer: A review of existing evidence
    Silvia Novello, Matteo Giaj Levra, Tiziana Vavalà · 2011 · Critical Reviews in Oncology/Hematology
  35. Doxycycline Regulated Induction of AKT in Murine Prostate Drives Proliferation Independently of p27 Cyclin Dependent Kinase Inhibitor Downregulation
    Hongyun Wang, Youyuan Xu, Zi Fang, Sen Chen, Steven P. Balk, Xin Yuan · 2012 · PLoS ONE
  36. Carbonic anhydrase IX as a predictive biomarker of response to kidney cancer therapy
    Sabina Signoretti, Meredith M. Regan, Michael B. Atkins · 2008 · British Journal of Urology
  37. Effects of pantoprazole as a HIF-1α inhibitor on human gastric adenocarcinoma sgc-7901 cells
    Yonghua Shen, Yue Wu, M. Chen, W. Shen, Shenglan Huang, L. Zhang, Xiaoping Zou · 2011 · Neoplasma
  38. Upregulation of Bcl-2 and Its Promoter Signals in CD4+ T Cells during Neuromyelitis Optica Remission
    Tao Yang, Su Wang, Xiao Yang, Qi Zheng, Lei Wang, Qian Li, Mingyan Wei, Zongpan Du, Yongping Fan · 2017 · Frontiers in Neuroscience
  39. Synergistic anti-proliferative effect of mTOR inhibitor (rad001) plus gemcitabine on cholangiocarcinoma by decreasing choline kinase activity
    Gigin Lin, Kun‐Ju Lin, Frank Wang, Tse‐Ching Chen, Tzu‐Chen Yen, Ta‐Sen Yeh · 2018 · Disease Models & Mechanisms
  40. Shotgun approach based comparative proteomic analysis of levo-tetrahydropalmatine-induced apoptosis in hepatocytes
    Chen Wang, Jiang‐Rui Zhou, Shuowen Wang, Mingliang Ye, Guorong Fan, Hanfa Zou, Chun‐Lei Jiang · 2010 · Toxicology Letters
  41. Molecular Mechanisms of Apoptosis in Prostate Cancer
    Petra Isabel Lorenzo, Yke Jildouw Arnoldussen, Fahri Saatcioglu · 2007 · Critical Reviews™ in Oncogenesis
  42. Correlation of Glucose Metabolism with Cancer and Intervention with Traditional Chinese Medicine
    Guihua Lai, Fei Wang, Duorui Nie, Shujun Lei, Zhuojun Wu, Jianxiong Cao, Lan-lan Tang · 2022 · Evidence-based Complementary and Alternative Medicine
  43. From genomics to functions: preclinical mouse models for understanding oncogenic pathways in prostate cancer.
    Chuan Yu, Kevin M. Hu, Daniel Nguyen, Zhu A. Wang · 2019 · PubMed Central
  44. SCAMP2/5 as diagnostic and prognostic markers for acute myeloid leukemia
    Can Yue, Siting Xie, Jiaying Zhong, Haijun Zhao, Zhijuan Lin, Li Zhang, Bing Xu, Yiming Luo · 2021 · Scientific Reports
  45. Therapeutic strategies for head and neck cancer based on p53 status
    Ichiro Ota, Noritomo Okamoto, Katsunari Yane, Akihisa Takahashi, Takashi Masui, Hiroshi Hosoi, Takeo Ohnishi · 2012 · Experimental and Therapeutic Medicine
  46. Establishment of a mouse model of troglitazone‐induced liver injury and analysis of its hepatotoxic mechanism
    Ru Jia, Shingo Oda, Koichi Tsuneyama, Yuya Urano, Tsuyoshi Yokoi · 2019 · Journal of Applied Toxicology
  47. Superior cancer preventive efficacy of low versus high dose of mTOR inhibitor in a mouse model of prostate cancer
    Marina P. Antoch, Michelle M. Wrobel, Bryan M. Gillard, Karen K. Kuropatwinski, Ilia A. Toshkov, Anatoli S. Gleiberman, Ellen Karasik, Michael T. Moser, Barbara A. Foster, Ekaterina L. Andrianova et al. · 2020 · Oncotarget
  48. Does aberrant membrane transport contribute to poor outcome in adult acute myeloid leukemia?
    Alexandre Chigaev · 2015 · Frontiers in Pharmacology
  49. Fatty acid extract from CLA-enriched egg yolks can mediate transcriptome reprogramming of MCF-7 cancer cells to prevent their growth and proliferation
    Aneta Agnieszka Koronowicz, Paula Banks, Dominik Domagała, Adam Master, Teresa Leszczyńska, Ewelina Piasna-Słupecka, Mariola Marynowska, Piotr M. Laidler · 2016 · Genes & Nutrition
  50. Hypoxia, Gene Expression, and Metastasis
    Olga V. Razorenova, Amato J. Giaccia · 2010 · Springer eBooks
  51. Akt-directed metabolic alterations in cancer
    Georgia Hatzivassiliou, Charalambos Babis Andreadis, Craig B. Thompson · 2005 · Drug Discovery Today Disease Mechanisms
  52. Identification of prostate cancer modifier pathways using parental strain expression mapping
    Qing Xu, Pradip K. Majumder, Kenneth N. Ross, Yeonju Shim, Todd R. Golub, Massimo F. Loda, William R. Sellers · 2007 · Proceedings of the National Academy of Sciences
  53. Targeted therapies for prostate cancer
    Ekatherine Asatiani, Edward Paul Gelmann · 2005 · Expert Opinion on Therapeutic Targets
  54. Correction: Rapamycin Inhibits IGF-1-Mediated Up-Regulation of MDM2 and Sensitizes Cancer Cells to Chemotherapy
    Wei Dong Du, Yong Yi, Haibo Zhang, Johann S. Bergholz, Junfeng Wu, Haoqiang Ying, Yujun Zhang, Zhi‐Xiong Jim Xiao · 2013 · PLoS ONE
  55. Interactions between key genes and pathways in prostate cancer progression and therapy resistance
    Fan Wu, Hengsen Zhang, Miaomiao Hao · 2025 · Frontiers in Oncology
  56. Determining PTEN Functional Status by Network Component Deduced Transcription Factor Activities
    Linh My Tran, Chun-Ju Chang, Seema B. Plaisier, Shumin Wu, Julie H. T. Dang, Paul S. Mischel, James C. Liao, Thomas G. Graeber, Hong Wu · 2012 · PLoS ONE
  57. HepaCAM Regulates Warburg Effect of Renal Cell Carcinoma via HIF-1α/NF-κB Signaling Pathway
    Yanru Fan, Liping Ou, Jiaxin Fan, Li Luo, Xiaohou Wu, Chunli Luo, Yingying Gao, Lingfang Niu · 2018 · Urology
  58. Regulatory Functions of Hypoxia in Host–Parasite Interactions: A Focus on Enteric, Tissue, and Blood Protozoa
    Emily DeMichele, Olivia Sosnowski, André G. Buret, Thibault Allain · 2023 · Microorganisms
  59. Phase I study of sapanisertib (CB‐228/TAK‐228/MLN0128) in combination with ziv‐aflibercept in patients with advanced solid tumors
    Niamh Coleman, Bettzy Stephen, Siqing Fu, Daniel D. Karp, Vivek Subbiah, Jordi Ahnert Rodon, Sarina Anne Piha-Paul, John Wright, Senait N. Fessahaye, Fengying Ouyang et al. · 2024 · Cancer Medicine
  60. Everolimus sensitizes Ras-transformed cells to radiation in vitro through the autophagy pathway
    Yu‐Chieh Su, Chih‐Chia Yu, Fei‐Ting Hsu, Shu‐Ling Fu, Jeng‐Jong Hwang, Ling-Chien Hung, Moon‐Sing Lee, Wen‐Yen Chiou, Hon‐Yi Lin, Shih‐Kai Hung · 2014 · International Journal of Molecular Medicine
  61. A novel rapid-onset high-penetrance plasmacytoma mouse model driven by deregulation of cMYC cooperating with KRAS12V in BALB/c mice
    Yiguo Hu, Mei Zheng, Reddy R. Gali, Z Tian, Güllü Görgün, Nikhil C. Munshi, Constantine S. Mitsiades, Kenneth Carl Anderson · 2013 · Blood Cancer Journal
  62. Gene expression profiling in R-flurbiprofen-treated prostate cancer: R-Flurbiprofen regulates prostate stem cell antigen through activation of AKT kinase
    Marina Zemskova, William J. Wechter, Svetlana Bashkirova, Chien-Shing Chen, Robert Evan Reiter, Michael B. Lilly · 2006 · Biochemical Pharmacology
  63. Rapamycin inhibits AR signaling pathway in prostate cancer by interacting with the FK1 domain of FKBP51
    Jing Zhang, Dan Wu, Yong‐Xing He, Lanlan Li, Shanhui Liu, Jianzhong Lu, Huiming Gui, Yuhan Wang, Yan Tao, Hanzhang Wang et al. · 2020 · Biochemistry and Biophysics Reports
  64. Expression genomics and drug development: Towards predictive pharmacology
    E. T. Liu · 2005 · Briefings in Functional Genomics and Proteomics
  65. Potential Role of Mammalian Target of Rapamycin Inhibitors in Breast Cancer Therapy
    Funda Meric‐Bernstam, Francisco J. Esteva · 2005 · Clinical Breast Cancer
  66. Growth Signaling Networks Orchestrate Cancer Metabolic Networks
    Brendan D. Manning, Christian C. Dibble · 2024 · Cold Spring Harbor Perspectives in Medicine
  67. Prognostic and Predictive Factors for Renal Cell Carcinoma
    Cristina Suárez, Marc Campayo, Romà Bastús, S. Sandoval Fernández del Castillo, Olatz Etxanitz, Marta Guix, Núria Sala, Enrique Gallardo · 2018 · Targeted Oncology
  68. Toxicity and adverse effects of everolimus in the treatment of advanced nonsmall cell lung cancer pretreated with chemotherapy-Chinese experiences
    Hu Yuanjia, Shunchang Jiao, Ju Dong Yang, Shengjie Sun, J Wang · 2015 · Indian Journal of Cancer
  69. Everolimus in pediatric transplantation
    Lars Pape, Rainer Ganschow, Thurid Ahlenstiel · 2012 · Current Opinion in Organ Transplantation
  70. Complex interaction of adiponectin-mediated pathways on cancer treatment: a novel therapeutic target
    Massimo Monks, Foivos Irakleidis, Haoning Peng · 2019 · Journal of Cancer Metastasis and Treatment
  71. The Future of Molecular-Targeted Cancer Chemoprevention
    Scott Michael Lippman · 2008 · Gastroenterology
  72. Overcoming resistance to mTOR inhibition for enhanced strategies in clinical trials
    Aung Naing · 2013 · Expert Opinion on Investigational Drugs
  73. Nutrient-Deprived Retinal Progenitors Proliferate in Response to Hypoxia: Interaction of the HIF-1 and mTOR Pathway
    Helena Khaliullina, Nicola K. Love, William A. Harris · 2016 · Journal of Developmental Biology
  74. Nilotinib alleviated acetaminophen-induced acute hepatic injury in mice through inhibiting HIF-1alpha/VEGF-signaling pathway
    Gehad M Menisy, Sherine Zakaria, Ghada Mohamed Suddek · 2022 · International Immunopharmacology
  75. Transgenic Expression of Polyomavirus Middle T Antigen in the Mouse Prostate Gives Rise to Carcinoma
    Sang‐Hyun Lee, Shidong Jia, Yanni Zhu, Tamara Utermark, Sabina Signoretti, Massimo F. Loda, Brian S. Schaffhausen, Thomas M. Roberts · 2011 · Journal of Virology
  76. The role of murine models of prostate cancer in drug target discovery and validation
    Imran Ahmad, Owen James Sansom, Hing Y. Leung · 2009 · Expert Opinion on Drug Discovery
  77. Oxygen deprivation provokes melanoma
    Amy E. Adams, Yakov Chudnovsky, Paul A. Khavari · 2006 · Nature Medicine
  78. Approaches to Target the Genome and Its Epigenome in Cancer
    Nadine Chapman‐Rothe, Robert Eldon Brown · 2009 · Future Medicinal Chemistry
  79. Hypoxia-inducible factor as a transcriptional factor regulating gene expression in cancer cells
    Ewelina Dondajewska, Wiktoria Maria Suchorska · 2011 · Współczesna Onkologia
  80. Sodium selenite induces apoptosis and inhibits autophagy in human synovial sarcoma cell line SW982 in�vitro
    Le Yang, Yongsong Cai, Ke Xu, Jia‑Lin Zhu, Yuan‐Bo Li, Xiaoqing Wu, Jian Sun, Shemin Lu, Peng Xu · 2018 · Molecular Medicine Reports
  81. Lobaplatin Enhances Radioactive 125I Seed-Induced Apoptosis and Anti-Proliferative Effect in Non-Small Cell Lung Cancer by Suppressing the AKT/mTOR Pathway
    Jia-hui Rong, Dong Li, Yuliang Li · 2021 · OncoTargets and Therapy
  82. Computational Methods for Learning Bayesian Networks from High-Throughput Biological Data
    Bradley McIntosh Broom, Devika Subramanian · 2006 · Cambridge University Press eBooks
  83. Cell Signaling Modifiers in Prostate Cancer
    Franklin L. Chen, Andrew J. Armstrong, Daniel J. George · 2008 · The Cancer Journal
  84. Interfering with cell‐survival signalling as a treatment strategy for prostate cancer
    Niall M. Corcoran, Anthony J. Costello, Christopher M. Hovens · 2006 · British Journal of Urology
  85. Gene Expression Signature Correlates with Outcomes in Metastatic Renal Cell Carcinoma Patients Treated with Everolimus Alone or with a Vascular Disrupting Agent
    Eddy Shih-Hsin Yang, Amin H. Nassar, Elio Adib, Opeyemi A. Jegede, Sarah Abou Alaiwi, Deborah L. Della Manna, David A. Braun, Mahsa Zarei, Heng Du, Sumanta Kumar Pal et al. · 2021 · Molecular Cancer Therapeutics
  86. Furfural Produces Dose-Dependent Attenuating Effects on Ethanol-Induced Toxicity in the Liver
    Zhuo Cheng, Xuanmei Luo, Zixin Zhu, Yonghui Huang, Xiue Yan · 2022 · Frontiers in Pharmacology
  87. First evidence of changes in enzyme kinetics and stability of glucokinase affected by somatic cancer-associated variations
    Miroslav Těšínský, Daniela Šimčíková, Petr Heneberg · 2018 · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics
  88. Hormone Refractory Prostate Cancer: Lessons Learned from the PTEN Prostate Cancer Model
    David J. Mulholland, Jing Jiao, Hong Wu · 2008 · Advances in experimental medicine and biology
  89. Assessing the Clinical Relevance of Oncogenic Pathways in Neoadjuvant Breast Cancer
    Paolo Verderio · 2012 · Journal of Clinical Oncology
  90. Hexokinases in gastrointestinal cancers: From molecular insights to therapeutic opportunities
    Guodong Liang, Yuehan Ma, Ping Deng, Shufeng Li, Chunyan He, Hao He, Hairui Liu, Yunda Fan, Ze Li · 2025 · Seminars in Oncology
  91. Multiple signal pathways in the leukemogenesis and therapeutic implications
    Jiezhong Chen, Nigel A.J. McMillan · 2007 · Leukemia Research
  92. Chaperon‑mediated autophagy can promote proliferation and invasion of renal carcinoma cells and inhibit apoptosis through PKM2
    Shangwen Xiao, Gang Xu, Zhenlong Wang, Tie Chong · 2021 · Oncology Reports
  93. Two novel TSC2 mutations in renal epithelioid angiomyolipoma sensitive to everolimus
    Tao Wang, Shunqiang Xie, Rongtuan Luo, Lianguo Shi, Peide Bai, Xuegang Wang, Rui Wan, Jiang Deng, Zhun Wu, Wei Li et al. · 2019 · Cancer Biology & Therapy
  94. New Insights into Prostate Cancer Biology
    Bala S. Balakumaran, Phillip G. Febbo · 2006 · Hematology/Oncology Clinics of North America
  95. mTOR inhibition and adult T-cell leukemia
    Chikara Hirase, Yasuhiro Maeda, Terufumi Yamaguchi, Junichi Miyatake, Akihisa Kanamaru · 2009 · Leukemia & lymphoma/Leukemia and lymphoma
  96. Akacid-medical-formulation, a novel biocidal oligoguanidine with antitumor activity reduces S-phase in prostate cancer cell lines through the Erk 1/2 mitogen-activated protein kinase pathway
    Hannes Neuwirt, Hansgeorg Müller, Ilaria Teresa Rita Cavarretta, Martin Tiefenthaler, Georg C. Bartsch, Guenther Konwalinka, Zoran Čulig · 2006 · International Journal of Oncology
  97. Direct Evidence of Target Inhibition with Anti-VEGF, EGFR, and mTOR Therapies in a Clinical Model of Wound Healing
    Jingquan Jia, Andrew E. Dellinger, Eric S. Weiss, Anuradha Bulusu, Christel N. Rushing, Haiyan Li, Leigh A. Howard, Neal Kaplan, Herbert Pang, Herbert I. Hurwitz et al. · 2015 · Clinical Cancer Research
  98. Physiologic and Molecular Basis of PET in Cancer Imaging
    Abhishek Mahajan, Gary Cook · 2016 · Springer eBooks
  99. The gene expression profile and cell of origin of canine peripheral T-cell lymphoma
    Eileen Owens, Lauren J. Harris, Adam Harris, Janna A. Yoshimoto, Robert Burnett, Anne C. Avery · 2024 · BMC Cancer
  100. Combination Strategies Targeting Hypoxia Inducible Factor 1 (HIF-1) for Cancer Therapy
    Annamaria Rapisarda, Giovanni Melillo · 2010 · Springer eBooks